Other languages Johnson & Johnson Deutsche Boerse AG

Equities

Real-time Estimate Tradegate Other stock markets 05:31:56 2024-07-03 am EDT			5-day change	1st Jan Change
135.9 ^EUR	-0.01%		-1.16%	-4.19%

Jul. 02	J&J: promising results in multiple myeloma	CF
Jul. 02	Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	MT

Momentum Picks T3 2024: 5 valores para el verano	Jul. 02
Momentum Picks Q3 2024: vijf aandelen voor de zomer	Jul. 02
J&J : résultats prometteurs dans le myélome multiple	Jul. 02
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	Jul. 02
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	Jul. 02
Momentum Picks Q3 2024: 5 azioni per l'estate	Jul. 01
Momentum Picks T3 2024 : 5 actions pour l'été	Jul. 01
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	Jul. 01
Nouveau semestre, nouvel état d'esprit	Jul. 01
Borsa di Italia: Un nuovo semestre, un nuovo umore	Jul. 01
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	Jul. 01
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	Jun. 28
J&J Unit's Rybrevant Combo Gets EU Approval	Jun. 28
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	Jun. 28
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	Jun. 28
Dealmakers optimistic on global M&A prospects despite sluggish growth	Jun. 28
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	Jun. 27
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	Jun. 24
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	Jun. 24
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	Jun. 21

No results for this search

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST